FDA approves Cosentyx to treat active non-radiographic axial spondyloarthritis.- Novartis
Novartis, announced that the FDA has approved Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), confirming Cosentyx efficacy in addressing the axial spondyloarthritis (axSpA) disease… read more.